



Title of Invention

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI : Assist. Prof. Hao-Chieh Chiu
Department of Clinical Laboratory Sciences and
Medical Biotechnology, National Taiwan U.

Experience:

<http://www.mc.ntu.edu.tw/departement/clsmb/>
<http://homepage.ntu.edu.tw/~hcchiu/indexc.htm>

Market Needs:

Sepsis caused by methicillin-resistant *S. aureus* (MRSA)

Our Technology:

1. Small molecule agent (MW<600 Da)
2. One-step, fully synthesized
3. Bactericidal agent
4. Active against Gram-positive pathogenic bacteria, including Methicillin-resistant *Staphylococcus aureus* (MRSA), Vancomycin-intermediate resistant *Staphylococcus aureus* (VISA), Vancomycin-resistant *Staphylococcus aureus* (VRSA), & Vancomycin-resistant *Enterococcus* (VRE).
5. Superior biofilm eradicating activity than vancomycin, linezolid and daptomycin
6. No cross resistance. *Staphylococcus aureus* cannot develop resistance to this drug
7. MIC < 1 mg/L, ED50 \cong 10mg/kg

Strength:

1. No resistance; The usage of this drug can be increased
2. A small-molecule agent; The synthesis can be easily scale-up and low-cost.

Competing Products:


Linezolid (Zyvox), Daptomycin (Cubicin)

Intellectual Properties:

1. US provisional patent has been applied.
2. The team has years of experience in anti-infective drug development

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw



This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.